Shiaw-Yih (Phoebus) Lin, Ph.D.
Department of Systems Biology, Division of Discovery Science
About Dr. Lin
My lab works on DNA damage response and cancer. I have a solid background in cancer biology and genetics, with specific training and expertise in genome maintenance. I trained with Dr. Stephen Elledge in the field of DNA damage response. Since establishing my own research group at MD Anderson, I have built upon my research strengths to establish research projects in the areas of genome maintenance and cancer suppression. My research accomplishments in these areas have led to my being awarded several major grants (three NIH R01 grants, an Era of Hope Scholar Award and an Innovator and Scholar Concept Award from DOD, and a Research Scholar Award from the American Cancer Society). Importantly, as the principal investigator for these grants, I have led these projects, effectively collaborating with other experts and publishing our important findings as the corresponding author in high-ranking journals, including including Cancer Cell (three papers), Annals of Oncology (two papers), Nature Cell Biology (one paper), Nature Communications (two papers), Science Translational Medicine (one paper), and PNAS (two papers). All of these accomplishments demonstrate the high productivity and success of my research program.
In addition to the mechanistic studies of DNA damage response network in suppressing genomic instability and cancer development, we have been developing translation research to target the defects of DNA damage responses in cancer for cancer prevention, early cancer detection and targeted therapy. Using the approaches of systems biology, we have established a gene signature that can predict if cells are defective in homologous recombination DNA repair and therefore are sensitive to PARP inhibitor treatment. We also have identified a gene signature that represents replication stress response defects in cells with oncogenic stress. Intriguingly, this RSR defect gene signature highly resembles the signature of cancer initiation cells, supporting the notion that RSR defect upon oncogenic stress is a key step that leads to cellular transformation and cancer initiation. Currently, we are developing nano-imaging and nano-targeting agents to detect and target these RSR defect cells for early cancer detection and cancer prevention.
Present Title & Affiliation
Primary Appointment
Professor, Department of Systems Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Department Chair, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Faculty Member, MD Anderson UTHealth Houston Graduate School, Houston, Texas
Education & Training
Degree-Granting Education
| 1999 | The University of Texas MD Anderson Cancer Center, Houston, Texas, US, Ph.D. in Cancer Biology |
| 1996 | State University of New York (SUNY) at Buffalo, Buffalo, New York, US, M.S. in Molecular Pharmacology |
| 1987 | Kaohsiung Medical College, Kaohsiung, TW, BS in Pharmacy |
Postgraduate Training
| 2015-2016 | Leadership, Faculty Leadership Academy, MD Anderson Cancer Center, Houston, Texas |
| 2000-2003 | Research Fellowship, Baylor College of Medicine, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - 2015
Assistant Professor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2003 - 2009
Administrative Appointments/Responsibilities
Chief, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2023
Deputy Chair, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - Present
Extramural Institutional Committee Activities
Member, Scientific Review Committee # 3 (SRC 3), The University of Texas MD Anderson Cancer Center, 2022 - 2024
Member, Center for Clinical and Translational Sciences (CCTS) TL1 Advisory Board, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, GSBS Student Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Institutional Research Grants Program (Basic Research Projects), The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Search Committee in Health Economics, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, GSBS Therapeutics and Pharmacology Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2025
Member, GSBS Admissions Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2021
Member, Faulty Achievement Awards committee, The University of Texas MD Anderson Cancer Center, 2017 - 2025
Member, MDACC Graduate Education Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Member, Faculty Senate Research Affairs Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2024
Member, Faculty Appeals Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2016
Faculty Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2013 - 2019
Member, Research Laboratory Space Subcommittee of the Research Council, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Consulting Member, Technology Review Committee for Institutional Grants, The University of Texas MD Anderson Cancer Center, 2012 - 2016
member, ACS-IRG Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Member, GSBS Therapeutics and Pharmacology Program Awards Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2019
member, Study Section Review Committee for Sister Institution Network Funding (SINF) Program, The University of Texas MD Anderson Cancer Center, 2011 - 2017
Member, Technology Review Committee for Institutional Grants, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Institutional Research Grants Program (Basic Research Projects), The University of Texas MD Anderson Cancer Center, 2007 - 2010
Member, Faculty Mentoring Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2011
Member, GSBS McGovern Student Poster Contest Judging Committee, The University of Texas MD Anderson Cancer Center, 2007
Member, Scientific Publications Advisory Board, The University of Texas MD Anderson Cancer Center, 2006 - Present
Member, GSBS Cancer Biology Program Admissions Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008
Editorial Activities
Editor/Service on Editorial Board(s), CANCER DIAGNOSIS & PROGNOSIS, 2021 - Present
Member of Editorial Review Board, Clinical Oncology Research Journal, 2018 - Present
Member of Editorial Review Board, Journal of Bioinformatics, Computational and Systems Biology, 2014 - Present
Member of Editorial Review Board, International Journal of Stem Cell Research, 2014 - Present
Member of Editorial Review Board, Annals of Translational Medicine, 2013 - 2020
Editor, International Journal of Cancer Therapy and Oncology, 2013 - Present
Member of Editorial Review Board, Experimental Hematology & Oncology, 2012 - Present
Member of Editorial Review Board, ISRN Cell Biology, 2011 - 2018
Member of Editorial Review Board, World Journal of Translational Medicine, 2011 - Present
Senior Editorial Board Member, American Journal of Cancer Research, 2011 - Present
Member of Editorial Review Board, Frontiers in Molecular and Cellular Oncology, 2011 - Present
Member of Editorial Review Board, World Journal of Clinical Oncology, 2010 - 2020
Honors & Awards
| 2014 | George and Barbara Bush Endowment for Innovative Cancer Research, MDACC |
| 2011 | Faculty Scholar Award, MDACC |
| 2010 | Era of Hope Scholar Award, DOD Breast Cancer Research Program |
| 2006 | Research Scholar Award, American Cancer Society |
| 2001 | NIH National Research Service Award, NIH |
| 1998 | Predoctoral Award, US Army Medical Research and Materiel Command |
| 1997 | Predoctoral Fellowship, Meadows Foundation, MD Anderson Cancer Center |
| 1995 | Dean Award for Graduate Research, Roswell Park Cancer Center |
| 1987 | B.S. Honors in Pharmacy, Kaohsiung Medical College |
| 1985 - 1986 | Outstanding Scholarship, Kaohsiung Medical College |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. LP-184: A Novel Alkylating Agent Enhancing Adjuvanticity to Improve Immune Checkpoint Therapy in Triple-Negative Breast Cancer. Invited. Boston, MA, US.
- 2025. LP-184: A Novel Alkylating Agent Enhancing Adjuvanticity to Improve Immune Checkpoint Therapy in Triple-Negative Breast Cancer. Invited. Houston, TX, US.
- 2024. Cytosolic DNA Accumulation Converts Cold Tumor Microenvironments to Immunogenic, Enhancing Immunotherapy Efficacy in Breast Cancer. Invited. Vancouver, CA.
- 2024. Cytosolic DNA Accumulation Converts Cold Tumor Microenvironments to Immunogenic, Enhancing Immunotherapy Efficacy in Breast Cancer. Invited. Philadelphia, Pennsylvania, US.
- 2024. Signature-Guided Approaches for Targeting DNA Damage Response Defects in Cancer. Invited. Dallas, Texas, US.
- 2023. Deficiencies in Replication Stress Responses as Predictors for Immune Checkpoint Blockade Efficacy in Nonhypermutated Tumors. Invited. Honolulu, Hawaii, US.
- 2023. Deficiencies in Replication Stress Responses as Predictors for Immune Checkpoint Blockade Efficacy in Nonhypermutated Tumors. Invited. Urbana, Illinois, US.
- 2022. Signature-Guided Approaches for Targeting DNA Damage Response Defects in Cancer. Invited, Delaware, US.
- 2021. Signature-Guided Approaches for Targeting DNA Damage Responses Defects in Cancer. Invited. Houston, Texas, US.
- 2019. Signature-Guided Approaches for Targeting DNA Damage Response Defects in Cancer. Invited. Houston, Texas, US.
- 2018. Signature-Guided Precision Cancer Therapy. Invited. Providence, Rhode Island, US.
- 2017. Signature-Guided Approaches for Targeting DNA Damage Response Defects. Galveston, Texas, US.
- 2013. DNA Damage Response Defects as Biomarkers for Early Cancer Detection and Targeted Therapy. Stony Brook, New York, US.
- 2012. Replication Stress Response Defects in Cancer. San Antonio, Texas, US.
- 2011. DNA Damage Response in Cancer: From Biological Studies to Clinical Applications. Invited. Houston, Texas, US.
- 2010. Characterization of Novel Key Molecules in Genome Maintenance and Tumor Suppression. Invited. Chapel Hill, North Carolina, US.
- 2007. BRIT1 Regulates DNA Damage Response Chromosomal integrity and Cancer. Invited. Houston, Texas, US.
- 2007. BRIT1 Regulates DNA Damage Response Chromosomal integrity and Cancer. Invited. Kansas City, Missouri, US.
- 2006. BRIT1 Regulates DNA Damage Response Chromosomal integrity and Cancer. Invited. Philadelphia, Pennsylvania, US.
- 2005. BRIT1: Roles in immortalization, checkpoints and cancer. Invited. Galveston, Texas, US.
- 2005. The role of BRIT1 in DNA damage checkpoint. Invited. Houston, Texas, US.
National Presentations
- 2022. Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer. Invited. Preclinical Immuno-Oncology, US.
- 2022. Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer. Invited. Biomarkers & Precision Oncology World Congress. Boston, Massachusetts, US.
- 2020. Signature-Guided Approaches To Predict And Enhance Immuno-Oncology Response. Invited. Advances In Immuno-Oncology Congress USA, US.
- 2020. Replication Stress Response Defects Predict responses to ICT in Non-hypermutated tumors. Invited. San Antonio, Texas, US.
- 2020. Replication Stress Response Defects Predict ICB response in Non-hypermutated Cancers. Invited, US.
- 2019. Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages. Invited. National Harbor, Maryland, US.
- 2018. Signature-guided therapy for mismatch repair defective cancers. Invited. MD Anderson Gynecologic SPORE. Houston, Texas, US.
- 2018. Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies. Invited. Washington, DC, US.
- 2017. Integrative Network Analysis Reveals Rampant Signaling Cascade Rewiring and Vulnerabilities in Distinct Breast Cancer Subtypes. Invited. Long Island, New York, US.
- 2017. Signature-Guided Precision Cancer Therapy. Invited. Baltimore, Maryland, US.
- 2017. Replication Stress Response Defects Predict ICB response in Non-hypermutated Cancers. Invited, US.
- 2014. The replication stress response defect is associated with tumor-initiating cell formation. Poster. San Diego, California, US.
- 2014. TUSC4 functions as tumor suppressor by regulating BRCA1 stability and functions. Poster. San Diego, California, US.
- 2014. A potential new mechanism for PTEN to maintain genome stability. Poster. San Diego, California, US.
- 2013. A signature that predicts deficiency of homologous recombination DNA repair. Invited. Washington DC, US.
- 2013. Systematic Approaches to Characterize and Target DNA Damage Response Defects in Cancer. Invited. 3rd World Congress on Cancer Science & Therapy. San Francisco, California, US.
- 2013. A robust gene signature predicting deficient homologous recombination DNA repair. Invited. 4th International Conference on Biomarkers & Clinical Research. Philadelphia, Pennsylvania, US.
- 2008. The role of BRIT1/MCPH1 in chromatin remodeling and DNA damage response. Invited. San Diego, California, US.
- 2007. BRIT1/MCPH1 regulates early DNA damage response, chromosomal integrity, and cancer. Invited. Keystone Conferences on Genomic Instability and Repair. Breckenridge, Colorado, US.
International Presentations
- 2023. Deficiencies in Replication Stress Responses as Predictors for Immune Checkpoint Blockade Efficacy in Nonhypermutated Tumors. Invited. 6th International Conference on Breast Cancer Research and Therapeutics. Zoom, US.
- 2022. Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer. Invited. Taipei, TW.
- 2019. Characterize and target defective HR repair and replication stress response in triple negative breast cancer. Invited. London, GB.
- 2018. Signature-Guided Approaches for Targeting DNA Damage Response Defects. Invited. Oslo, NO.
- 2017. Signature-Guided Approaches for Targeting DNA Damage Response Defects. Invited. Hangzhou, CN.
- 2017. Signature-Guided Precision Cancer Therapy. Invited. Dubai, AE.
- 2015. Establish a novel gene signature predicting homologous recombination defect and develop optimal combination therapies for triple negative breast cancer. Invited. International Summit on Antimicrobial Agents and Chemotherapy. Valencia, ES.
- 2015. The Role of Dormancy in Promoting Breast Cancer Malignancy. Invited. The 15th SCBA International Symposium. Taipei, TW.
- 2014. Replication Stress Response Defect and Cancer Stemness. Invited. 4th World Congress on Cell Science & Stem Cell Research. Valencia, ES.
- 2014. Systematic Approaches to Characterize and Target DNA Damage Response Defects in Cancer. Invited. PCS Global Cancer Conference-2014 (GCC-2014). Athens, GR.
- 2013. A Robust Gene Signature Predicting Deficient Homologous Recombination DNA Repair. Invited. Calgary, CA.
- 2013. A molecular portrait of the homologous recombination DNA repair network via genome-wide transcriptome profiling. Invited. Crete, GR.
- 2013. A Robust Gene Signature Predicting Deficient Homologous Recombination DNA Repair. Invited. Banff, CA.
- 2012. Characterizing and targeting DNA damage response defects in Cancer. Invited. Changsha, CN.
- 2012. Characterizing and targeting DNA damage response defects in cancer. Invited, TW.
- 2011. DNA Damage Response in Cancer: From Biological Studies to Clinical Applications. Invited. Nanjian, CN.
- 2011. DNA Damage Response in Cancer: From Biological Studies to Clinical Applications. Invited. Changsha, CN.
- 2010. Characterization of Novel Key Molecules in Genome Maintenance and Tumor Suppression. Invited. Beijing, CN.
- 2010. Characterization of Novel Key Molecules in Genome Maintenance and Tumor Suppressio. Invited. 2010 International Cancer Biology Symposium. Kaohsiung, TW.
- 2010. Characterization of Novel Key Molecules in Genome Maintenance and Tumor Suppression. Invited. Beijing, CN.
- 2008. The role of BRIT1/MCPH1 in chromatin remodeling, DNA damage response and cancer. Invited. 8th International Conference of Anticancer Research. Kos, GR.
- 2008. The role of BRIT1/MCPH1 in chromatin remodeling and DNA damage response. Invited. Puerto Vallarta, MX.
- 2007. BRIT1 regulates DNA damage response chromosomal integrity and cancer. Invited. 2007 International Cancer Biology Symposium. Kaohsiung, TW.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | Assessing the Effect of LP-184 on Inducing Replication Stress, Innate Immunity, and Potentiating Immune Checkpoint Blockade in Triple Negative Breast Cancer |
| Funding Source: | Lantern Pharma |
| Role: | PI |
| ID: | AWD00008149 |
| Date: | 2022 - 2024 |
| Title: | Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma |
| Funding Source: | NIH/NIDCR |
| Role: | CO-I |
| ID: | R03DE031333 |
| Date: | 2021 - 2024 |
| Title: | Characterization and targeting NOTCH activated Adenoid Cystic Carcinoma (ACC) |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | CO-I |
| ID: | W81XWH2110409 |
| Date: | 2021 - 2026 |
| Title: | RNase H2 is a novel therapeutic target in triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1-R01CA251206 |
| Date: | 2021 - 2024 |
| Title: | Leveraging proteome instability to potentiate immune checkpoint blockade in MSI-high colorectal cancer |
| Funding Source: | MD Anderson Bridge Funding |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA247862 |
| Date: | 2017 - 2023 |
| Title: | Project 1: High grade cancers: capitalizing on PARPness in ovarian carcinoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1P50CA217685-01 |
| Date: | 2017 - 2023 |
| Title: | Signature-guided therapy for mismatch repair defective cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA218287 |
| Date: | 2017 - 2017 |
| Title: | UTMDACC Uterine SPORE Developmental Research Program |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 16012310 |
| Date: | 2013 - 2017 |
| Title: | Regulation of HECT E3 ubiquitin ligases by Rak kinase: a novel mechanism that links tyrosine phosphorylation to protein stability in breast tumor suppression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP130310 |
| Date: | 2013 - 2020 |
| Title: | Characterizing and targeting CHD4 Deficiency in Endometrial Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA172490 |
| Date: | 2012 - 2014 |
| Title: | Molecular Determinants and Clinical Implications of Breast Cancer Dormancy |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-12-1-0372 |
| Date: | 2010 - 2011 |
| Title: | Rak, A New Player In The DNA Damage Response Network |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| ID: | KG101226 |
| Date: | 2010 - 2016 |
| Title: | Targeting replication stress response defects in breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-10-1-0558 |
| Date: | 2008 - 2010 |
| Title: | Genetic and Chemical Screens for Suppressors of Oct4 Expression in Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | PI |
| ID: | KG080389 |
| Date: | 2006 - 2013 |
| Title: | Functional and clinical analysis of Rak in breast cancer suppression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA120960 |
| Date: | 2006 - 2010 |
| Title: | Functional analysis of a novel tumor suppressor, BRIT1 in prostate cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | RSG-06-192-01-MGO |
| Date: | 2005 - 2011 |
| Title: | The roles of BRIT1 in immortalization, checkpoints and cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01-CA112291 |
| Date: | 2005 - 2006 |
| Title: | Functional and clinical analysis of Rak in breast cancer suppression |
| Funding Source: | UTMDACC M. Scott Memorial Fund for Breast Cancer Research |
| Role: | PI |
| Date: | 2004 - 2005 |
| Title: | The roles of BRIT1 in immortalization, checkpoints and cancer |
| Funding Source: | UTMDACC IRG |
| Role: | PI |
| Date: | 2003 - 2003 |
| Title: | Chk2: Roles in checkpoint and breast tumor suppression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | NIH 1-F32-CA093043-01 |
| Date: | 1999 - 2015 |
| Title: | Targeting the BRCAness and P13Kness in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2 P50CA083639 |
Selected Publications
Peer-Reviewed Articles
- Nguyen TQA, Zhang J, Dai H, Cifci A, Du Y, McGrail D, Meric-Bernstam F, Lin SY. Targeting RNase H2: A Dual Mechanism Strategy to Elevate Replication Stress, DNA Damage, and Antitumor Immunity in Triple-Negative Breast Cancer. Cell Rep Med. e-Pub 2025.
- Siqueira, JM, Mitani, Y, Marques-Piubelli, ML, Hoff, CO, Bonini, F, De Sousa, LG, Mitani, M, Carvalho, GL, Nunes, FD, De Matos, LL, Lin, S, Spiotto, MT, Hanna, EY, McGrail, DJ, El-Naggar, AK, Ferrarotto, R. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype. Journal of Oral Pathology and Medicine 54(8):658-666, 2025. e-Pub 2025. PMID: 40624990.
- Wang Y, Xie H, Ma J, Du T, Gao S, Lin SY, Liang D. Drug Metabolism and Pharmacokinetic Evaluation of a Novel RNase H2 Inhibitor for the Treatment of Triple-Negative Breast Cancer. Pharmaceutics 17(8):1052, 2025. e-Pub 2025. PMID: 40871073.
- de Sousa, LG, Siqueira, JM, McGrail, DJ, Marques-Piubelli, ML, Neto, FL, Borgogno, SF, Nunes, FD, De Matos, LL, Kowalski, LP, Hoff, CO, Dai, H, Mitani, Y, Li, K, Williams, MD, Lin, S, El-Naggar, AK, Sikora, AG, Burks, JK, Gillison, M, Ferrarotto, R. The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
- Siqueira JM, Mitani Y, Hoff CO, Bonini F, Guimaraes de Sousa L, Marques-Piubelli ML, Purushothaman A, Mitani M, Dai H, Lin SY, Spiotto MT, Hanna EY, McGrail DJ, El-Naggar AK, Ferrarotto R. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol 37(1):100371, 2024. e-Pub 2024. PMID: 38015043.
- McGrail DJ, Li Y, Smith RS, Feng B, Dai H, Hu L, Dennehey B, Awasthi S, Mendillo ML, Sood AK, Mills GB, Lin SY, Yi SS, Sahni N. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med 4(11):101255, 2023. e-Pub 2023. PMID: 37909041.
- Zhang J, Dai H, Huo L, Burks J, McGrail D, Lin SY. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway. J Immunother Cancer 11(10):e007560, 2023. e-Pub 2023. PMID: 37907220.
- Sousa LG, McGrail DJ, Lazar Neto F, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Spardy Burr N, Cooper ZA, Kinneer K, Cortez MA, Lin SY, Bell D, El Naggar A, Burks J, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res 29(16):3162-3171, 2023. e-Pub 2023. PMID: 37256648.
- Wang Y, Ma J, Lin SY, Xie H, Liang D. A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies. J Pharm Biomed Anal 228:115326, 2023. e-Pub 2023. PMID: 36924633.
- Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, ICON Team GD. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform(6):e2200040, 2022. e-Pub 2022. PMID: 35944232.
- Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 10(3):e004371, 2022. e-Pub 2022. PMID: 35241495.
- Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2):e003082, 2022. e-Pub 2022. PMID: 35110355.
- Shih DJH, Ruoxing L, Müller P, Zheng WJ, Do KA, Lin SY, Carter SL. CNGPLD: Case-control copy-number analysis using Gaussian process latent difference. Bioinformatics 38(8):2096-101, 2022. e-Pub 2022. PMID: 35176131.
- Shih DJH, Chen MK, Yin J, McGrail DJ, Dai H, Wei R, Zhang J, Zheng WJ, Do KA, Yang L, Hung MC, Lin SY. Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer. Am J Cancer Res 12(1):337-354, 2022. e-Pub 2022. PMID: 35141022.
- Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
- McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY. Replication stress response defects are associated with response to immune checkpoint blockade in non-hypermutated cancers. Sci Transl Med 13(617):eabe6201, 2021. e-Pub 2021. PMID: 34705519.
- Lindemann A, Patel AA, Tang L, Tanaka N, Gleber-Netto FO, Bartels MD, Wang L, McGrail DJ, Lin SY, Frank SJ, Frederick MJ, Myers JN, Osman AA. Combined inhibition of Rad51 and Wee1 enhances cell killing in HNSCC through induction of apoptosis associated with excessive DNA damage and replication stress. Mol Cancer Ther 20(7):1257-1269, 2021. e-Pub 2021. PMID: 33947685.
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, S-Y L. High tumor mutation burden fails to predict immune checkpoint blockade response across solid tumors. Annals of Oncology 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
- Wei R, Dai H, Zhang J, Shih D, Liang Y, Xiao P, McGrail DJ, S-Y L. A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches. Int. J. Mol. Sci 22:5008, 2021. e-Pub 2021. PMID: 34066883.
- Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res 27(3):852-864, 2021. e-Pub 2021. PMID: 3172898.
- Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res 10(11):3947-3972, 2020. e-Pub 2020. PMID: 33294279.
- Li Y, Burgman B, McGrail DJ, Sun M, Qi D, Shukla SA, Wu E, Capasso A, Lin SY, Wu CJ, Eckhardt SG, Mills GB, Li B, Sahni N, Yi SS. Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Res 80(21):4854-4867, 2020. e-Pub 2020. PMID: 32855206.
- Liang Y, Yu L, Zhang D, Zhao X, Gao H, Slagle BL, Goss JA, Wang X, Li K, Lin SY. BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. Am J Cancer Res 10(6):1900-1918, 2020. e-Pub 2020. PMID: 32642299.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
- Wang J, McGrail D, Bhupal P, Zhang W, K-Y L, Ku Y, Lin T, Wu H, Tsai K, Li K, C-Y P, Finegold M, Lin SY, and Tsai R. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Molecular Cancer Research 18(5):723-734, 2020. e-Pub 2020. PMID: 32051231.
- McGrail D, Garnett J, Yin J, Dai H, Shih D, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu K, Broaddus R, Mills GB, Sahni N & Lin SY. Proteome instability is a therapeutic vulnerability in mismatch repair deficient cancer. Cancer Cell 37(3):371-386, 2020. e-Pub 2020. PMID: 32109374.
- Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867, 2019. e-Pub 2019.
- Lin T, Lin TC, McGrail DJ, Bhupal PK, Ku YH, Zhang W, Meng L, Lin SY, Peng G, Tsai RYL. Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene 38(20):3919-3931, 2019. e-Pub 2019.
- Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer 144(5):1092-1103, 2019. e-Pub 2019.
- Li Y, Liu Q, McGrail D, Dai H, Li K, Lin SY. CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. Am J Cancer Res 8(5):903-914, 2018. e-Pub 2018.
- McGrail DJ, Lin CC, Dai H, Mo W, Li Y, Stephan C, Davies P, Lu Z, Mills GB, Lee, JS, Lin SY. Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. Cell Rep 23:2095–2106, 2018. e-Pub 2018.
- McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SY, Sahni N. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9(1):1317, 2018. e-Pub 2018.
- Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416, 2018. e-Pub 2018.
- Kim, JL, Ha, GH, Campo, L, Denning, MF, Patel, TB, Osipo, C, Lin, S, Breuer, E. The role of Rak in the regulation of stability and function of BRCA1. Oncotarget 8(49):86799-86815, 2017. e-Pub 2017. PMID: 29156836.
- Li Y, Sahni N, Pancsa R, McGrail DJ, Xu J, Hua X, Coulombe-Huntington J, Ryan M, Tychhon B, Sudhakar D, Hu L, Tyers M, Jiang X, Lin SY, Babu MM, Yi S. Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer. Cell Rep 21(3):798-812, 2017. e-Pub 2017.
- Wang W, Zhao J, Wen X, C-J LC, Li J, Huang Q, Yu Y, S-Y L, and Li C. MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media & Molecular Imaging 2017, 2017. e-Pub 2017.
- Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS, Li K. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene 36(20):2910-2918, 2017. e-Pub 2017.
- Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392):eaal5148, 2017. e-Pub 2017.
- Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv 3(4):e1600957, 2017. e-Pub 2017.
- McGrail DJ, Lin CCJ, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, CP Vellano CP, Hennessy B, Mills GB, S-Y &L. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. npj Systems Biology and Applications 3:Article number:8, 2017. e-Pub 2017.
- Mo W, Liu Q, CC-J L, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, S-Y L. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 22(7):1699-1712, 2016. e-Pub 2016.
- Huang S, Tu W, Ju Z, Poage GM, Cai CR, Brewster A, S-Y L, Mills GB, Wang H and Peng G. A Five-Gene Signature Inferred from Transcriptome Profiling of Homologous Recombination-Mediated DNA Repair Predicts Clinical Outcome of Patients with Cancer. Jacobs Journal of Biomarkers 2(1), 2016. e-Pub 2016.
- Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 17(9):1158-68, 2015. e-Pub 2015. PMID: 26237645.
- Liang Y, Gao H, Lin SY, Goss JA, Du C, Li K. Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model. Oncogene 34(33):4368-78, 2015. e-Pub 2015. PMID: 25362854.
- Lee HJ, Lan L, Peng G, Chang WC, Hsu MC, Wang YN, Cheng CC, Wei L, Nakajima S, Chang SS, Liao HW, Chen CH, Lavin M, Ang KK, Lin SY, Hung MC. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res 25(2):225-36, 2015. e-Pub 2015. PMID: 25601159.
- Peng Y, Dai H, Wang E, Lin CC, Mo W, Lin S-Y PG&. TUSC4 functions as a tumor suppressor by regulating BRCA1’s stability via the E3 ubiquitination pathway. Cancer Research 75(2):378-386, 2015. e-Pub 2015. PMID: 25480944.
- Gong L, Govan J, Evans E, Dai H, Wang E, S-Y L, Li J, Lin HK, Lazar A, Lin S-Y MGA. Nuclear PTEN tumor-suppressive functions through maintaining normal heterochromatin structure. Cell Cycle 14(14):2323-32, 2015. e-Pub 2015.
- Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014. e-Pub 2014. PMID: 24553445.
- Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, Wang G, Peng G, S-Y L. BRIT1 Regulates p53 Stability and Functions as a Tumor Suppressor in Breast Cancer. Carcinogenesis 34(10):2271-2280, 2013. e-Pub 2013. PMID: 23729656.
- Tian F, Sharma S, Zou J, S-Y L, Wang B, Rezvani K, Wang H, Parvin JD, Ludwig T, Canman CE, Zhang D. BRCA1 promotes the ubiquitination of PCNA and recruitment of translesion polymerases in response to replication blockade. Proc. Natl. Acad. Sci U S A 110(33):13558-63, 2013. e-Pub 2013. PMID: 23901102.
- Hu R, Wang E, Peng G, Dai H, S-Y L. Zinc Finger Protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle 12(13):2033-41, 2013. e-Pub 2013. PMID: 23777805.
- Meng L, Lin T, Peng G, Hsu J, Lee S, S-Y L, Tsai R. Nucleostemin Deletion Reveals An Essential Mechanism That Maintains The Genomic Stability of Stem and Progenitor Cells. Proc Natl Acad Sci U S A 110(28):11415-20, 2013. e-Pub 2013. PMID: 23798389.
- Trinh BQ, Ko SY, Barengo N, Lin SY, Naora H. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Research 73(2):1000-10, 2013. e-Pub 2013. PMID: 23222298.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
- Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human Nuclease/helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Res 72(11):2802-13, 2012. e-Pub 2012. PMID: 22491672.
- Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 287(9):6764-72, 2012. e-Pub 2012. PMID: 22219182.
- Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-34, 2011. e-Pub 2011. PMID: 21852383.
- Zhang W, Peng G, Lin SY, Zhang P. DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells. J Biol Chem 286(41):35899-905, 2011. e-Pub 2011. PMID: 21878640.
- Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J Biol Chem 286(32):28599-607, 2011. e-Pub 2011. PMID: 21676867.
- Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-6137, 2010. e-Pub 2010. PMID: 20802511.
- Ishiguro T, Avila H, Lin SY, Nakamura T, Yamamoto M, Boyd DD. Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. Br J Cancer 102(4):774-782, 2010. e-Pub 2010. PMID: 20087350.
- Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K. BRIT1/MCPH1 is Essential for Mitotic and Meiotic Recombination DNA Repair and Maintaining Genomic Stability in Mice. PLoS Genet 6(1):e1000826, 2010. e-Pub 2010. PMID: 20107607.
- Liang Y, Gao H, Lin SY, Goss JA, Brunicardi FC, Li K. siRNA-Based Targeting of Cyclin E Overexpression Inhibits Breast Cancer Cell Growth and Suppresses Tumor Development in Breast Cancer Mouse Model. PLoS One 5(9):e12860, 2010. e-Pub 2010. PMID: 20877462.
- Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, Hu R, Li K, Lin SY. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Nat Cell Biol 11(7):865-872, 2009. e-Pub 2009. PMID: 19525936.
- Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. Cancer Cell 15(4):304-314, 2009. e-Pub 2009. PMID: 19345329.
- Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, Lin SY, Safari A, Liu D, Songyang Z. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol 16(4):372-379, 2009. e-Pub 2009. PMID: 19287395.
- Rai R, Phadnis A, Haralkar S, Badwe RA, Dai H, Li K, S-Y L. Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 7(14):2225-33, 2008. e-Pub 2008. PMID: 18635967.
- Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 103(41):15014-9, 2006. e-Pub 2006. PMID: 17018644.
- Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10(2):145-57, 2006. e-Pub 2006. PMID: 16872911.
- Lin SY, Rai R, Li K, Xu ZX, Elledge SJ. BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A 102(42):15105-9, 2005. e-Pub 2005. PMID: 16217032.
- Lin SY, Li K, Stewart GS, Elledge SJ. Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A 101(17):6484-6489, 2004. e-Pub 2004. PMID: 15096610.
- Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E overexpressing hepatocellular carcinoma. Cancer Res 63(13):3593-3597, 2003. e-Pub 2003. PMID: 12839946.
- Lin SY, Elledge SJ. Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase. Cell 113(7):881-889, 2003. e-Pub 2003. PMID: 12837246.
- Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2(4):323-34, 2002. e-Pub 2002. PMID: 12398896.
- Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3(9):802-8, 2001. e-Pub 2001. PMID: 11533659.
- Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97(8):4262-6, 2000. e-Pub 2000. PMID: 10759547.
- Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275(11):8027-31, 2000. e-Pub 2000. PMID: 10713122.
- Wen Y, Yan DH, Spohn B, Deng J, Lin SY, Hung MC. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Res 60(1):42-6, 2000. e-Pub 2000. PMID: 10646849.
- Shao R, Hu MC, Zhou BP, Lin SY, Chiao PJ, von Lindern RH, Spohn B, Hung MC. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 274(31):21495-8, 1999. e-Pub 1999. PMID: 10419449.
- Black AR, Jensen D, S-Y L, Azizkhan JC. Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 274(3):1207-15, 1999. e-Pub 1999. PMID: 9880488.
- Kiyokawa N, Lee EK, Karunagaran D, Lin SY, Hung MC. Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. J Biol Chem 272(30):18656-65, 1997. e-Pub 1997. PMID: 9228035.
- S-Y L, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 16(4):1668-75, 1996. e-Pub 1996. PMID: 8657142.
Invited Articles
- Zhang J, Chan DW, Lin SY. Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer. Biomedicines 10(11):2775, 2022. e-Pub 2022. PMID: 36359297.
- Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci 29(1):83, 2022. e-Pub 2022. PMID: 36253762.
- Lin RA, Lin JK, Lin SY. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung J Med Sci 37(6):448-458, 2021. e-Pub 2021. PMID: 33636043.
- Zhang J, Shih DJH, Lin SY. Role of DNA Repair Defects in Predicting Immunotherapy Response. Biomark Res 8(23), 2020. e-Pub 2020. PMID: 32612833.
- Lin JK, Lin SY. Leveraging immunogenic cell death to potentiate immune checkpoint therapy in cancer. Trends in Cancer Res 15, 2020. e-Pub 2020.
- Zhang J, Shih DJH, Lin SY. The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response. J Cancer Res Cell Ther 3(1):052, 2019. e-Pub 2019. PMID: 32577620.
- Pan MR, Li K, Lin SY, Hung WC. Connecting the Dots: From DNA Damage and Repair to Aging. Int J Mol Sci 17(5):685, 2016. e-Pub 2016.
- Peng Y, Wang E, Peng G, and Lin SY. Ubiquitination assay for mammalian cells. Bio-protocol 6(14):e1880, 2016. e-Pub 2016.
- IP CKM, Yin J, Ng PKS, Lin SY, Mills GB. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science 3(4):386-416, 2016. e-Pub 2016.
- Wang SH, Lin SY. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Exp Hematol Oncol 2(1):19, 2013. e-Pub 2013.
- Wang E, Lin SY. Brit1 regulates DNA damage repair and chromosome dynamics to suppress tumor phenotypes. Trends in Cancer Research 8:1-10, 2012. e-Pub 2012.
- Lin SY, Liang Y, Li K. Multiple Roles of BRIT1/MCPH1 in DNA Damage Response, DNA Repair, and Cancer Suppression. Yonsei Med J 51(3):295-301, 2010. e-Pub 2010. PMID: 20376879.
- Peng G, Lin, S-Y. BRIT1/MCPH1 is a multifunctional DNA damage responsive protein mediating DNA repair-associated chromatin remodeling. Cell Cycle 8(19):3071-3072, 2009. e-Pub 2009.
- Peng G, Lin SY. The linkage of chromatin remodeling to genome maintenance: contribution from a human disease gene BRIT1/MCPH1. Epigenetics 4(7):457-461, 2009. e-Pub 2009. PMID: 19829069.
- Yim EK, Siwko S, Lin SY. Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle 8(15):2360-2364, 2009. e-Pub 2009. PMID: 19597351.
- Liang Y, Lin SY, Brunicardi FC, Goss J, Li K. DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment. World J Surg 33(4):661-666, 2009. e-Pub 2009. PMID: 19034564.
- Jackson-Bernitsas D, Li K, S-Y L. BRIT1 gene in cancer. Encyclopedia of Cancer Springer 2:428-430, 2008. e-Pub 2008.
- Rai R, Peng G, Li K, S-Y L. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 4(2):99-106, 2007. e-Pub 2007. PMID: 17804872.
- Chaplet M, Rai R, Jackson-Bernitsas D, Li K, Lin SY. BRIT1/MCPH1: a guardian of genome and an enemy of tumors. Cell Cycle 5(22):2579-83, 2006. e-Pub 2006. PMID: 17172830.
- Lin, S-Y, M-C H. Cancer: Current concepts. J. Clinical Ligand Assay 22:1-5, 1999. e-Pub 1999.
Review Articles
- Seviour EG, Lin SY. The DNA damage response: Balancing the scale between cancer and ageing. Aging (Albany NY) 2(12):900-7, 2010. e-Pub 2010. PMID: 21191148.
- Lin, S, Hung, M. Cancer. Journal of Clinical Ligand Assay 22(4):326-330, 1999. e-Pub 1999.
Editorials
- Zhang, D, Lin, S, Lee, M. Exploring genomic instability of cancers: applications in diagnosis and treatment. Frontiers in Cell and Developmental Biology 13, 2025. PMID: 39989984.
- Lin S-Y EEA. New insights into tumor dormancy: Targeting DNA repair pathways. World J Clin Oncol 6(5):80-88, 2015.
- Davis JD, Lin SY. DNA damage and breast cancer. World J Clin Oncol 2(9):329-338, 2011. PMID: 21909479.
- Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2(2):73-79, 2011. PMID: 21603316.
Book Chapters
- Gong L, Wang E, Lin SY. Chromatin Remodeling in DNA Damage Response and Human Aging. In: Chromatin Remodeling. Intech, 153-171, 2013.
- Green L, Lin SY. DNA Damage Response and Breast Cancer: An Overview. In: Breast Cancer Cells / Book 2. InTech, 97-112, 2012.
- Peng, G, Lin, S. Emerging roles of BRIT1/MCPH1 in genome maintenance and tumor suppression, 133-147, 2011.
- Peng G, S-Y L. A Novel DNA Damage Responsive Protein Dysfunctioned in Primary Microcephaly and Cancer. In: New Research on DNA Damage. Nova Publishers, 99-112, 2008.
- Azizkhan JC, S-Y L, Jensen D, Kostic D and Black AR. Retinoblastoma protein, gene expression, and cell cycle control. In: Cancer Genes: Functional Aspects. Plenum, 1996.
Letters to the Editor
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol 33: 1204-1206, 2022.
- Bourguignon L, Lan KH, Singleton P, Lin, Shiaw-Yih, Yu DH, M-C H. Localizing the EGF receptor – Reply. Nature Cell Biology 4: E22-E23, 2002.
Patents
- Lin CJ, Peng G, Lin SY, Mills GB. Gene Signature to Predict Homologous Recombination (HR) Deficient Cancer. Patent Number: U.S. Pat. No. 9,850,542.
- Lin SY, McGrail DJ, Mills GB. Gene Signatures to Predict Drug Response in Cancer. Patent Number: U.S. Pat. No. 11,447,830.
Patient Reviews
CV information above last modified March 26, 2026